Big moment from @tompowles1. The pearl for fellows: KEYNOTE-905 tested EV plus pembrolizumab in cisplatin-ineligible patients and KEYNOTE-B15 in cisplatin-eligible ones, which is w

MeDucation· @MeDucationai · X·2026-10-23 00:04· 3 天前评分70

正文 · 原文

Big moment from @tompowles1. The pearl for fellows: KEYNOTE-905 tested EV plus pembrolizumab in cisplatin-ineligible patients and KEYNOTE-B15 in cisplatin-eligible ones, which is why this approval covers both. #ESMO26 #BladderCancer

89 浏览 · 1 赞 · 1 转发 · 0 回复

会议摘要

4733O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905

https://esmocongress.esmo.org

NCT03924895NCT03924895按 - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) 对上

- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

https://esmocongress.esmo.org

引用@

Perioperative EVP for MIBC approved in Europe by the EMA irrespective of platinum eligibility. This is based on B15/KN905 with ⬆️ ⬆️ pCR, EFS & OS vs previous standard of care. More patients will get systemic therapy (cisplatin obstacles won’t exist) and these patients will have better outcomes. Will VOLGA tell us more about the optimal number of cycles #ESMO26 ? Which patients don’t need surgery (EV209, EV309, TROFUSE55). Will ctDNA help us?

在 X 查看被引用的帖子

来源：MeDucation · x.com